- Home
- UPST vs ARQT Comparison
UPST vs ARQT Comparison
Compare UPST & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UPST | ARQT |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.9B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | UPST | ARQT |
|---|---|---|
| Price | $30.50 | $24.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 6 |
| Target Price | ★ $45.84 | $34.00 |
| AVG Volume (30 Days) | ★ 4.4M | 1.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 131.25 | 88.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,043,857,000.00 | $376,072,000.00 |
| Revenue This Year | $34.45 | $34.85 |
| Revenue Next Year | $32.64 | $29.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 63.99 | ★ 91.34 |
| 52 Week Low | $23.97 | $13.06 |
| 52 Week High | $85.31 | $31.77 |
Technical Indicators
Market Signals| Indicator | UPST | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 49.21 | 66.61 |
| Support Level | $29.14 | $22.41 |
| Resistance Level | $30.67 | $25.25 |
| Average True Range (ATR) | 2.13 | 0.94 |
| MACD | -0.05 | 0.48 |
| Stochastic Oscillator | 25.57 | 85.49 |
Price Performance
Historical ComparisonAbout UPST Upstart Holdings Inc.
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The company support development of different lending product offerings, which are grouped into three operating segments - Personal Lending (unsecured personal loans and small dollar loans), Auto Lending (auto refinance, auto retail loans, and auto secured personal loans), and Other (HELOCs and other).
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.